Alexei Tumanov | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Alexei Tumanov
The University of Texas at San Antonio, United States

Alexei Tumanov
Affiliation The University of Texas at San Antonio
Country United States
Google Scholar ID EDMA9agAAAAJ
Documents 97
Citations 7,514
h-index 41
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0001-6042-0152
Scopus 35351917100

Alexei Tumanov is an immunology researcher affiliated with the University of Texas at San Antonio and the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. Institutional and bibliographic sources describe his research in relation to cytokine signaling, lymphotoxin biology, immune regulation, lymphoid-organ biology, inflammation, cancer immunotherapy and neuroimmune mechanisms.[1][2]

Abstract

Alexei Tumanov’s research profile is centered on molecular and cellular immunology, with particular emphasis on lymphotoxin signaling and its relationship to immune-system organization, inflammatory responses and disease mechanisms. His institutional research record includes investigations of lymphotoxin-beta receptor signaling, innate and adaptive immune responses, cancer immunotherapy and neuroimmune interactions.[1] Recent publications have examined lymphotoxin-beta receptor regulation of chronic pain, ferroptosis-associated regulation of innate lymphoid cell responses, and strategies intended to separate antitumor activity from immune-mediated toxicity in CD137-directed cancer immunotherapy.[2][3]

Keywords

  • Immunology
  • Molecular Immunology
  • Lymphotoxin Signaling
  • Lymphotoxin-beta Receptor
  • Cytokine Biology
  • Innate Immunity
  • Cancer Immunotherapy
  • Neuroimmune Regulation
  • Inflammation

Introduction

Molecular immunology examines how signaling pathways, immune-cell interactions and tissue environments regulate protective immunity and inflammatory disease. Within this field, lymphotoxin signaling represents an important area for studying the organization and maintenance of lymphoid tissues and the communication between immune and non-immune cells. Tumanov’s research has addressed these mechanisms through experimental studies of lymphotoxin pathways and their roles in immune-system development and disease-related processes.[1]

His earlier work included conditional targeting studies of lymphotoxin pathways in lymphoid organs. Such research contributed to the characterization of cell-specific functions of lymphotoxin and lymphotoxin-beta receptor signaling in peripheral lymphoid-organ development and maintenance.[4] More recent work has extended this research framework to inflammatory bowel disease, cancer immunotherapy and neuroimmune signaling.[2][3]

Research Profile

Institutional information identifies Tumanov as a researcher in the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. His documented research interests include immune regulation, cytokine signaling and lymphotoxin biology. His research profile also encompasses interactions between immune pathways and pathological processes, including inflammation, cancer and chronic pain.[1][2]

The research program has included both fundamental and disease-oriented investigations. Earlier studies examined lymphotoxin-dependent organization of lymphoid organs, while later studies have investigated how related signaling mechanisms can influence therapeutic toxicity, inflammatory responses and sensory-neural processes.[4][5]

Research Contributions

A central contribution of Tumanov’s research is the investigation of lymphotoxin-beta receptor signaling as a regulator of immune and tissue processes. Experimental work has examined how this receptor pathway contributes to lymphoid-organ development and maintenance and how alterations in the pathway can affect inflammatory and pathological responses.[4]

In cancer immunotherapy, Tumanov has investigated mechanisms associated with the toxicity of CD137-directed treatment. A Cancer Prevention and Research Institute of Texas grant lists him as principal investigator for a project examining the role of lymphotoxin-beta receptor signaling in overcoming liver toxicity associated with anti-CD137 cancer immunotherapy.[5]

His recent collaborative research has also examined neuroimmune mechanisms. A 2026 Cell Reports publication reported that lymphotoxin-beta receptor signaling is involved in the development of chronic pain, providing experimental evidence connecting an immune signaling pathway with sensory processes.[3]

Additional work published in Cellular & Molecular Immunology examined ferroptosis in relation to ILC2 responses in inflammatory bowel disease. The article identifies lymphotoxin-related immunological research within a broader investigation of inflammatory mechanisms affecting innate lymphoid cells.[2]

Publications

Tumanov’s publication record spans molecular immunology, cytokine signaling, lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune regulation. His institutional profile lists publications including recent studies in Science Advances, Cell Reports and Cellular & Molecular Immunology.[1]

  • Tumanov, A. V., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.[3]
  • Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.[2]
  • Shein, S. A., Korchagina, A. A., Wang, L.-J., et al., including Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17), eaea8737.[1]
  • Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.[4]

Research Impact

The documented research program connects fundamental immunological mechanisms with disease-oriented questions. Institutional records describe grant-supported research into the regulation of cancer immunotherapy toxicity and the role of lymphotoxin-beta receptor signaling in sensory neurons, while recent publications extend the research into chronic pain and inflammatory bowel disease.[2][3][5]

The quantitative metrics supplied for this recognition profile list 97 documents, 7,514 citations and an h-index of 41. Such metrics are bibliographic indicators and should be interpreted according to the database, date of retrieval and author-profile methodology used. The supplied Google Scholar, ORCID and Scopus identifiers provide external routes for verification and updating of these records.

The translational relevance of the research is also reflected in grant-supported projects. CPRIT records identify Tumanov as principal investigator of research concerning anti-CD137 cancer immunotherapy and lymphotoxin-beta receptor signaling, illustrating an application-oriented dimension of his immunological research.[5]

Award Suitability

The documented research themes are closely associated with molecular and cellular immunology, including cytokine signaling, lymphotoxin biology, immune-cell regulation and disease mechanisms. His publication record and institutionally documented research projects provide identifiable evidence of sustained activity in these areas.[1][5]

For the purposes of the International Molecular Biologist Awards, the supplied recognition category is the Innovative Research Award. This article records the relationship between the stated award category and the documented research profile without assigning an independent assessment of scientific merit.

Conclusion

Alexei Tumanov’s research profile encompasses molecular immunology, lymphotoxin signaling and the regulation of immune responses in physiological and pathological settings. His documented work includes studies of lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune mechanisms. Recent publications demonstrate continuing investigation of lymphotoxin-beta receptor pathways and immune-cell regulation, while grant records document support for translational research involving cancer immunotherapy.[1][2][3][5]

References

  1. UT Health San Antonio. (n.d.). Tumanov, Alexei, M.D., Ph.D. — Microbiology, Immunology & Molecular Genetics. Institutional researcher profile.
    https://lsom.uthscsa.edu/mimg/team-member/alexei-v-tumanov-m-d-ph-d/
  2. Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.
    https://doi.org/10.1038/s41423-026-01404-z
  3. Tumanov, A. V., Mecklenburg, J. M., Belugin, S., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.
    https://doi.org/10.1016/j.celrep.2026.117269
  4. Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.
    https://doi.org/10.1034/j.1600-065X.2003.00071.x
  5. Cancer Prevention and Research Institute of Texas. (2022). Grant RP220470: Overcoming liver toxicity of anti-CD137 cancer immunotherapy. Principal Investigator: Alexei Tumanov. University of Texas Health Science Center at San Antonio.
    https://www.cprit.texas.gov/grants-funded/grants/rp220470

georges Bahr | Immunology | Innovative Research Award

Published on by Molecular Biologist

 

Innovative Research Award

              Georges Bahr
Researcher Georges Bahr
Affiliation University of Balamand
Country Lebanon
Scopus ID 7102520346
Documents 116
Citations 2,560
h-index 28
Subject Area Immunology
Event International Molecular Biologist Awards

Georges Bahr

University of Balamand, Lebanon

Georges Bahr is affiliated with the University of Balamand in Lebanon and has an indexed research profile in the field of immunology. The Innovative Research Award recognizes researchers whose scholarly work demonstrates sustained scientific activity, originality, and measurable contribution to their respective fields. According to the supplied Scopus profile information, the researcher has 116 documents, 2,560 citations, and an h-index of 28.[1]

Abstract

Georges Bahr’s academic profile reflects an established research record in immunology, supported by a substantial body of indexed scholarly publications and measurable citation activity. The supplied bibliometric data identify 116 documents, 2,560 citations, and an h-index of 28. These indicators provide quantitative evidence of research visibility and scholarly influence, while qualitative assessment of individual publications remains important when evaluating scientific innovation and significance.[1][2]

Keywords

Immunology, Molecular Biology, Cellular Immunology, Immune Response, Biomedical Research, Scientific Publications, Research Impact, Citation Analysis, Translational Research, Academic Excellence.

Introduction

Immunology is a multidisciplinary area of biomedical science concerned with the study of immune-system components, immune responses, host–pathogen interactions, inflammation, and mechanisms underlying immune-mediated disease. Contemporary immunological research frequently integrates molecular biology, cellular biology, genetics, microbiology, and clinical science to investigate mechanisms operating at multiple biological scales.[3]

Academic research profiles in immunology may be assessed using both qualitative and quantitative measures. Bibliometric indicators, including publication counts, citation counts, and the h-index, can provide useful contextual information regarding scholarly dissemination and influence, although they do not independently establish the scientific quality of individual studies.[2][4]

Research Profile

Georges Bahr is associated with the University of Balamand, Lebanon, and is represented in Scopus under author identifier 7102520346. The supplied profile records 116 documents and 2,560 citations, with an h-index of 28. These figures indicate a sustained publication record and citation presence within the indexed scholarly literature.[1]

  • Institutional affiliation: University of Balamand.
  • Country: Lebanon.
  • Primary subject area: Immunology.
  • Scopus author identifier: 7102520346.
  • Indexed documents: 116.
  • Reported citations: 2,560.
  • Reported h-index: 28.

Research Contributions

Research in immunology contributes to understanding the molecular and cellular mechanisms responsible for immune recognition, regulation, inflammation, host defense, and immune-associated disorders. Within this broad discipline, scholarly contributions can encompass experimental investigation, molecular characterization, cellular studies, disease mechanisms, and translational approaches. The available profile information establishes Georges Bahr’s disciplinary classification but does not provide sufficient evidence to assign specific individual discoveries or mechanisms without reviewing the underlying publications.[1][3]

The combination of publication activity and citation accumulation provides an indication that the researcher’s work has been disseminated within the scholarly literature. Detailed evaluation of originality, methodological rigor, reproducibility, and practical significance should be conducted at the publication level by subject-matter experts.[4]

Publications

The supplied Scopus information records 116 documents associated with Georges Bahr. Scopus provides bibliographic and citation information that can be used to examine publication output, citation patterns, collaboration, and subject-area distribution. Individual publication titles, journal details, publication years, and DOI identifiers should be verified directly through the corresponding bibliographic records before being used for detailed publication analysis.[1]

  • Total documents reported in the supplied Scopus profile: 116.
  • Research classification: Immunology.
  • Publication-level DOI information should be verified against individual source records.

Research Impact

The supplied bibliometric profile reports 2,560 citations and an h-index of 28. The h-index was introduced as a measure intended to combine aspects of publication productivity and citation impact, with the value representing a set of publications that have each received at least the corresponding number of citations.[4]

Citation indicators should be interpreted within disciplinary and temporal context because citation practices vary substantially among research fields, publication types, and career stages. Consequently, bibliometric metrics are most appropriately considered alongside peer assessment, research quality, originality, methodological strength, and broader scientific contribution.[2][5]

Award Suitability

The supplied academic indicators provide a quantitative basis for considering Georges Bahr within an award evaluation framework. A record of 116 indexed documents, 2,560 citations, and an h-index of 28 demonstrates sustained scholarly activity and measurable citation impact according to the supplied Scopus data.[1]

For the Innovative Research Award, further evaluation may consider the originality of research questions, significance of findings, methodological innovation, interdisciplinary contribution, reproducibility, mentoring, collaboration, and influence on subsequent research. Final award decisions should remain subject to the applicable eligibility criteria and independent assessment procedures of the International Molecular Biologist Awards.

Conclusion

Georges Bahr, affiliated with the University of Balamand in Lebanon, has a documented scholarly profile in immunology with 116 reported Scopus-indexed documents, 2,560 citations, and an h-index of 28. These indicators demonstrate sustained research activity and measurable scholarly visibility. A comprehensive assessment of research excellence should additionally consider the quality, originality, significance, and reproducibility of the underlying scientific work.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Georges Bahr, Author ID 7102520346. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7102520346
  2. Elsevier. (n.d.). Scopus: Abstract and citation database for peer-reviewed literature. Scopus.
    https://www.scopus.com/
  3. Murphy, K., & Weaver, C. (2016). Janeway’s Immunobiology (9th ed.). Garland Science.
    https://doi.org/10.1201/9781315533247
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Richard Schwartz | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

         Researcher Information
Researcher Richard Schwartz
Affiliation Michigan State University
Country United States
Scopus ID 7404170129
Documents 56
Citations 1,968
h-index 27
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0003-3151-2511
Google Scholar QBELV48AAAAJ

Richard Schwartz

Michigan State University, United States

Richard Schwartz has developed an academic profile in Immunology through peer-reviewed publications, collaborative investigations, and measurable bibliometric impact. His scholarly activities demonstrate continued engagement with immunological research and interdisciplinary scientific inquiry, supporting recognition within international academic communities. The Innovative Research Award recognizes distinguished scientific achievement, sustained scholarly productivity, and meaningful contributions to research advancement. [1]

Abstract

Richard Schwartz is an academic researcher whose work in immunology has contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and sustained research activity. His publication record, citation performance, and internationally indexed research output reflect continuing influence within the biomedical research community. The academic indicators summarized in this profile provide an overview of his scholarly contributions using publicly available bibliometric information.[1][2]

Keywords

Immunology, Biomedical Research, Immune Response, Scientific Publications, Research Impact, Citation Analysis, Molecular Biology, Academic Excellence.

Introduction

Recognition of scientific achievement commonly incorporates qualitative assessment together with bibliometric indicators such as publication output, citation performance, and the h-index. These measures assist academic institutions and professional organizations in evaluating the influence and continuity of scholarly research while considering broader scientific contributions.[3]

Research Profile

  • Affiliated with Michigan State University.
  • Primary research specialization in Immunology.
  • Author of 56 scholarly publications indexed in Scopus.
  • Research has received 1,968 citations with an h-index of 27.
  • Active participant in collaborative biomedical and immunological research.

Research Contributions

Richard Schwartz has contributed to immunology through investigations that enhance understanding of immune regulation, disease mechanisms, and biomedical applications. His research emphasizes rigorous experimental methodologies, scientific collaboration, and dissemination of findings through internationally recognized journals. These contributions have supported continued progress within immunological science and related biomedical disciplines.[2][4]

Publications

  • Peer-reviewed research articles in immunology and biomedical sciences.
  • Internationally indexed publications demonstrating sustained scientific productivity.
  • Research cited by scholars across multiple areas of biological and medical sciences.

Research Impact

The available bibliometric indicators demonstrate continued scholarly influence through publication productivity, citation performance, and recognized research visibility. Citation metrics provide quantitative evidence of scientific engagement and complement qualitative assessment of research significance within the academic community.[1][5]

Award Suitability

Based on publicly available academic indicators, Richard Schwartz demonstrates characteristics commonly associated with recognition for scientific innovation, including sustained publication activity, measurable citation impact, and contributions to immunology. Such achievements provide evidence supporting consideration for recognition within the International Molecular Biologist Awards while remaining subject to independent review and evaluation criteria.[3]

Conclusion

Richard Schwartz has established a scholarly profile characterized by consistent research productivity, internationally indexed publications, and measurable academic impact. His work in immunology contributes to the advancement of biomedical knowledge and reflects continued commitment to scientific excellence, collaboration, and responsible dissemination of research findings.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Richard Schwartz, Author ID 7404170129. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7404170129
  2. Google Scholar. (n.d.). Richard Schwartz – Google Scholar Citations.
    https://scholar.google.co.uk/citations?user=QBELV48AAAAJ&hl=en&oi=ao
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences.
    https://doi.org/10.1073/pnas.0507655102
  4. Orcid. Author details .Advances in immunological research and translational science.
    https://doi.org/10.1038/nri.2017.123
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Moutih Rafei | Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr. Moutih Rafei | Immunology | Best Researcher Award 

Full Professor | University of Montreal | Canada

Dr. Moutih Rafei is a Full Professor at the Université de Montréal’s Faculty of Medicine, Department of Pharmacology and Physiology. With extensive expertise in cellular and molecular immunology, he has significantly advanced the fields of immuno-oncology, vaccine engineering, and immune modulation. He earned his Ph.D. in Experimental Medicine from McGill University, followed by a post-doctoral fellowship in Molecular Biology at Université de Montréal, where he later established his own research laboratory. His group focuses on developing novel immune-based therapeutic strategies, several of which are progressing toward clinical application. Dr. Rafei has authored numerous high-impact publications, book chapters, and patents, contributing both to academic knowledge and industrial innovation. His leadership extends to mentoring young scientists and serving as an editor for scientific journals. His work continues to influence immunological research and therapeutic development, addressing complex diseases such as cancer, autoimmune disorders, and infectious conditions.

Professional Profile

Scopus

Google Scholar

Education

Dr. Rafei completed his B.Sc. Honours in Immunology at McGill University, conducting an honours thesis on Giardia lamblia transmission-blocking DNA vaccines. He pursued his Ph.D. in Experimental Medicine at McGill University, working under the supervision of Dr. Jacques Galipeau on fusokine design as a novel therapeutic strategy for immunosuppression. Following this, he undertook a post-doctoral fellowship at Université de Montréal under Dr. Claude Perreault, where he specialized in innate and classical CD8 T-cell development and maturation. Complementing his scientific training, he also completed a Mini-Entrepreneurship Program at the HEC-Poly-UdeM Entrepreneurship Centre, gaining strategic and managerial skills applicable to biotech ventures. This combination of academic depth and entrepreneurial insight has enabled Dr. Rafei to successfully navigate the interface between fundamental research and its translation into clinical and industrial solutions, shaping his career as both an academic leader and biotech innovator.

Experience

Dr. Rafei holds extensive academic and industrial experience, combining innovative research with strategic leadership in biotechnology. As a Full Professor at Université de Montréal, he leads a dynamic research program focused on immune engineering and translational immunotherapy. His industrial roles include serving as Chief Scientific Officer at Defence Therapeutics, where he oversaw pre-clinical development of oncology and vaccine programs, and Head of Discovery at Medicenna Therapeutics, managing the IL-2 Superkine program currently in clinical trials. He is also the Founder and CEO of Axiom Services Inc., providing consulting and R&D guidance to pharmaceutical and biotechnology companies. His responsibilities have included directing large-scale pre-clinical studies, preparing regulatory submissions for clinical trials, and presenting research at major international conferences. Through his dual academic and industry roles, Dr. Rafei has successfully bridged fundamental science and applied product development, positioning himself as a key contributor to innovation in immuno-oncology.

Research Interest

Dr. Rafei’s research centers on developing advanced immunotherapies for severe diseases, particularly cancer. His work covers T-cell biology, fusokine engineering, and mesenchymal stromal cell-based vaccines. He has pioneered the design of engineered mesenchymal stromal cells capable of presenting antigens for cancer immunotherapy, developed non-IL1Ralpha-binding IL-2 variants for oncology, and advanced γδ T-cell-based therapeutic platforms. He also leads projects utilizing the proprietary Accum® technology to enhance the targeted delivery of antibody-drug conjugates, cancer vaccines, and infectious disease vaccines. Additionally, his group explores genetic and pharmacological strategies to convert mesenchymal stromal cells into antigen-presenting cells, expanding potential treatments for oncology, autoimmune diseases, and transplantation. Integrating molecular biology, immune engineering, and translational medicine, his research aims to transform fundamental discoveries into effective, scalable, and clinically relevant therapies that address unmet medical needs in immunology.

Awards

Dr. Rafei has received more than twenty awards and recognitions that highlight his exceptional contributions to the fields of immunology and translational medicine. These honors acknowledge his pioneering work in cytokine and fusokine engineering, vaccine development, and mesenchymal stromal cell-based immunotherapies. His ability to integrate molecular innovations into practical clinical applications has earned him recognition in both academic and industrial sectors. Awards have also acknowledged his role as a mentor, fostering the growth of emerging scientists, and his leadership in driving collaborative research across disciplines and borders. His keynote presentations at prestigious international conferences further demonstrate his influence and leadership in the scientific community. The breadth of these awards reflects his sustained commitment to excellence, innovation, and the advancement of immune-based strategies for the treatment of complex and life-threatening diseases.

Top Noted Publications

Dr. Rafei has authored over sixty high-impact peer-reviewed articles, five reviews, two book chapters, one monograph, and holds six patents. His research has been published in leading journals such as Molecular Cancer, Frontiers in Immunology, and Cancer Immunology Research. With a citation index exceeding two thousand, his work has influenced both academic research and industry practices in immuno-oncology. His publications cover diverse topics, including engineered mesenchymal stromal cells for cancer vaccination, cytokine-fusion proteins, and novel delivery systems using the Accum® technology. In addition to original research, he has contributed reviews synthesizing developments in immune-based therapies.

Title: Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner – M Rafei, PM Campeau, A Aguilar-Mahecha, M Buchanan, P Williams, et al.

Journal: The Journal of Immunology

Year: 2009

Cited by 462.

Title: Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction – M Rafei, J Hsieh, S Fortier, MY Li, S Yuan, et al.

Journal: Blood

Year: 2008

Cited by 309.

Title: Cell therapy: types, regulation, and clinical benefits – AEH El-Kadiry, M Rafei, R Shammaa.

Journal: Frontiers in Medicine

Year: 2021

Cited by 238.

Title: Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis – M Rafei, E Birman, K Forner, J Galipeau.

Journal: Molecular Therapy

Year: 2009

Cited by 204.

Title: Nociceptor neurons affect cancer immunosurveillance – M Balood, M Ahmadi, T Eichwald, A Ahmadi, A Majdoubi, et al.

Journal: Nature

Year: 2022

Cited by 200.

Title: A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties – M Rafei, J Hsieh, S Zehntner, MY Li, K Forner, et al.

Journal: Nature Medicine

Year: 2009

Cited by 170.

Title: Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR 2 – K Mojumdar, F Liang, C Giordano, C Lemaire, G Danialou, et al.

Journal: EMBO Molecular Medicine

Year: 2014

Cited by 155.

Title: Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome – PM Campeau, M Rafei, MN Boivin, Y Sun, GA Grabowski, et al.

Journal: Blood

Year: 2009

Cited by 112

Conclusion

Dr. Moutih Rafei’s exceptional contributions to immunotherapy, translational science, and biotechnology innovation position him as an outstanding candidate for the Best Researcher Award. His career demonstrates a rare combination of groundbreaking scientific insight, creative problem-solving, and the capacity to turn laboratory discoveries into impactful therapies. Recognizing his achievements through this award would honor his significant contributions and encourage further advancements that have the potential to transform patient care globally.

Liu Yang | oncology | Best Researcher Award

Published on by Molecular Biologist

Prof Dr. Liu Yang | oncology | Best Researcher Award 

professor, The Affiliated Cancer Hospital of Nanjing Medical University, China.

Yang Liu is a Chief Physician and Associate Professor specializing in colorectal surgery. With expertise in minimally invasive and robotic surgeries, he performs over 150 advanced procedures annually. His contributions to medical research and patient care make him a key figure in the field of colorectal cancer treatment.

Profile

Scopus

Education

Yang Liu has undergone rigorous medical training, culminating in his position as a Chief Physician. He is an accomplished researcher and associate professor, continuously contributing to the development of colorectal cancer treatments.

Experience

Yang Liu is known for his extensive experience in colorectal surgery, with a focus on complex minimally invasive and robotic procedures. His surgical expertise, combined with his research on cancer genomics, has solidified his reputation in both clinical practice and academic settings.

Research Interests

Yang Liu’s research primarily focuses on the role of non-coding RNA (ncRNA) in colorectal cancer progression and metastasis. He is involved in various projects exploring epigenetic mechanisms and targeted therapies for colorectal cancer. His goal is to advance the understanding and treatment of this complex disease.

Awards

  • 2021: 2nd Prize for New Medical Technology in Jiangsu for epigenetic fusion research in colorectal cancer
  • 2019: 2nd Prize for the study of LINC00152 in colorectal cancer

Publications

  1. Multi-Dimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
  2. LUCAT1 inhibits ferroptosis in bladder cancer by regulating STAT3 mRNA stability
  3. Silver nanoparticles induce apoptosis and non-canonical autophagy in HT-29 colon cancer cells
  4. Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer

Conclusion

Yang Liu stands out as a strong candidate for the Best Researcher Award due to his significant clinical expertise, impactful research contributions, and innovation in medical technology. His leadership in colorectal surgery and mentorship roles, combined with a growing portfolio of high-impact publications and patents, underscore his potential for making groundbreaking advances in cancer treatment. To further enhance his candidacy, he could focus on increasing his international presence and broadening his research scope. Nonetheless, his accomplishments to date make him a highly competitive candidate for the award.